HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Langen, K.-J. Articles by Feinendegen, L.E. Search for Related Content PubMed PubMed Citation Articles by Langen, K.-J. Articles by Feinendegen, L.E.

The Influence of Plasma Glucose Levels on Fluorine-18-Fluorodeoxyglucose Uptake in Bronchial Carcinomas

Institute of Medicine and Institute of Nuclear Chemistry, Research Center, Jülich, Germany

Correspondence: For correspondence or reprints contact: Karl-Josef Langen, MD, Institute of Medicine, Research Center Jülich, POB 1913, 5170 Jülich, Germany.

ABSTRACT

PET studies with 2-¹⁸F-fluorodeoxyglucose (FDG) were carried out in 15 patients with bronchial carcinomas, first under fasting conditions and then 2 days later during intravenous infusion of a 20% glucose solution which raised the plasma glucose level from 84.6 ± 14.7 to 168.3 ± 23.6 mg/100 ml (n = 15, p < 0.001). Tumor metabolism was quantified by the dose absorption ratio (OAR) of FDG uptake [DAR = tissue concentration/(injected dose/body weight) and also by the rate of glucose consumption (MA) as measured by the Patlak graphical approach in 12 patients. The DAR decreased from 5.07 ± 1.89 under fasting conditions to 2.84 ± 0.97 (–41.8% ± 15%, n = 15, p < 0.001) during glucose infusion, while the MR remained constant (4.71 ± 2.38 mg/100 ml/min versus 4.96 ± 2.46 mg/100 ml/min, n = 12, ns). Correction of the DAR data by plasma glucose level eliminated the significant difference between the fasting and glucose load [4.24 ± 1.59 versus 4.70 ± 1.45 (n = 15, ns)], but considerable changes in individual patients remained. These data indicate that the DAR of FDG uptake in bronchial carcinomas is influenced significantly by plasma glucose levels. Dynamic quantification of glucose metabolism using the Patlak approach is less dependent on the plasma glucose level and appears advantageous when high reproducibility is needed.

This article has been cited by other articles:

				R. Kumar, S. Basu, D. Torigian, V. Anand, H. Zhuang, and A. Alavi Role of Modern Imaging Techniques for Diagnosis of Infection in the Era of 18F-Fluorodeoxyglucose Positron Emission Tomography Clin. Microbiol. Rev., January 1, 2008; 21(1): 209 - 224. [Abstract] [Full Text] [PDF]

				M. K. Gould, J. Fletcher, M. D. Iannettoni, W. R. Lynch, D. E. Midthun, D. P. Naidich, and D. E. Ost Evaluation of Patients With Pulmonary Nodules: When Is It Lung Cancer?: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 108S - 130S. [Abstract] [Full Text] [PDF]

				J. Meller, C.-O. Sahlmann, and A. K. Scheel 18F-FDG PET and PET/CT in Fever of Unknown Origin J. Nucl. Med., January 1, 2007; 48(1): 35 - 45. [Abstract] [Full Text] [PDF]

				B. J. Fueger, J. Czernin, I. Hildebrandt, C. Tran, B. S. Halpern, D. Stout, M. E. Phelps, and W. A. Weber Impact of Animal Handling on the Results of 18F-FDG PET Studies in Mice J. Nucl. Med., June 1, 2006; 47(6): 999 - 1006. [Abstract] [Full Text] [PDF]

				O. Mawlawi, J. J. Erasmus, R. F. Munden, T. Pan, A. E. Knight, H. A. Macapinlac, D. A. Podoloff, and M. Chasen Quantifying the Effect of IV Contrast Media on Integrated PET/CT: Clinical Evaluation Am. J. Roentgenol., February 1, 2006; 186(2): 308 - 319. [Abstract] [Full Text] [PDF]

				H. Nomori, N. Kosaka, K. Watanabe, T. Ohtsuka, T. Naruke, T. Kobayashi, and K. Uno 11C-Acetate Positron Emission Tomography Imaging for Lung Adenocarcinoma 1 to 3 cm in Size With Ground-Glass Opacity Images on Computed Tomography Ann. Thorac. Surg., December 1, 2005; 80(6): 2020 - 2025. [Abstract] [Full Text] [PDF]

				C.-y. O. Wong, J. Thie, K. J. Parling-Lynch, D. Zakalik, J. H. Margolis, M. Gaskill, J. Hill, F. Qing, D. Fink-Bennett, and C. Nagle Glucose-Normalized Standardized Uptake Value from 18F-FDG PET in Classifying Lymphomas J. Nucl. Med., October 1, 2005; 46(10): 1659 - 1663. [Abstract] [Full Text] [PDF]

				W. A. Weber Use of PET for Monitoring Cancer Therapy and for Predicting Outcome J. Nucl. Med., June 1, 2005; 46(6): 983 - 995. [Abstract] [Full Text] [PDF]

				H. Nomori, K. Watanabe, T. Ohtsuka, T. Naruke, K. Suemasu, and K. Uno Visual and Semiquantitative Analyses for F-18 Fluorodeoxyglucose PET Scanning in Pulmonary Nodules 1 cm to 3 cm in Size Ann. Thorac. Surg., March 1, 2005; 79(3): 984 - 988. [Abstract] [Full Text] [PDF]

				D. C.P. Cobben, P. H. Elsinga, H. J. Hoekstra, A. J.H. Suurmeijer, W. Vaalburg, B. Maas, P. L. Jager, and H. M.J. Groen Is 18F-3'-Fluoro-3'-Deoxy-L-Thymidine Useful for the Staging and Restaging of Non-Small Cell Lung Cancer? J. Nucl. Med., October 1, 2004; 45(10): 1677 - 1682. [Abstract] [Full Text] [PDF]

				D. C.P. Cobben, P. L. Jager, P. H. Elsinga, B. Maas, A. J.H. Suurmeijer, and H. J. Hoekstra 3'-18F-Fluoro-3'-Deoxy-L-Thymidine: A New Tracer for Staging Metastatic Melanoma? J. Nucl. Med., December 1, 2003; 44(12): 1927 - 1932. [Abstract] [Full Text] [PDF]

				C. J. Hoekstra, O. S. Hoekstra, S. G. Stroobants, J. Vansteenkiste, J. Nuyts, E. F. Smit, M. Boers, J. W.R. Twisk, and A. A. Lammertsma Methods to Monitor Response to Chemotherapy in Non-Small Cell Lung Cancer with 18F-FDG PET J. Nucl. Med., October 1, 2002; 43(10): 1304 - 1309. [Abstract] [Full Text] [PDF]

				R. M. Pieterman, T. H. Que, P. H. Elsinga, J. Pruim, J. W.G. van Putten, A. T.M. Willemsen, W. Vaalburg, and H. J.M. Groen Comparison of 11C-Choline and 18F-FDG PET in Primary Diagnosis and Staging of Patients with Thoracic Cancer J. Nucl. Med., February 1, 2002; 43(2): 167 - 172. [Abstract] [Full Text] [PDF]

				E. F. Patz Jr 1999 Plenary Session: Friday Imaging Symposium : Evaluation of Focal Pulmonary Abnormalities with FDG PET RadioGraphics, July 1, 2000; 20(4): 1182 - 1185. [Full Text] [PDF]

				I. C. Smith, A. E. Welch, A. W. Hutcheon, I. D. Miller, S. Payne, F. Chilcott, S. Waikar, T. Whitaker, A. K. Ah-See, O. Eremin, et al. Positron Emission Tomography Using [18F]-Fluorodeoxy-D-Glucose to Predict the Pathologic Response of Breast Cancer to Primary Chemotherapy J. Clin. Oncol., April 1, 2000; 18(8): 1676 - 1688. [Abstract] [Full Text] [PDF]

				V. J Lowe and K. S Naunheim Current role of positron emission tomography in thoracic oncology Thorax, August 1, 1998; 53(8): 703 - 712. [Full Text]

				W. Romer, A.-R. Hanauske, S. Ziegler, R. Thodtmann, W. Weber, C. Fuchs, W. Enne, M. Herz, C. Nerl, M. Garbrecht, et al. Positron Emission Tomography in Non-Hodgkin's Lymphoma: Assessment of Chemotherapy With Fluorodeoxyglucose Blood, June 15, 1998; 91(12): 4464 - 4471. [Abstract] [Full Text] [PDF]

				V. J. Lowe and K. S. Naunheim Positron Emission Tomography in Lung Cancer Ann. Thorac. Surg., June 1, 1998; 65(6): 1821 - 1829. [Abstract] [Full Text] [PDF]